Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ABBV NYSE:GSK NYSE:NVO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$223.09+0.3%$203.75$163.81▼$225.16$393.01B0.534.69 million shs5.99 million shsGSKGSK$40.91+0.6%$38.95$31.72▼$42.63$82.74B0.533.63 million shs3.07 million shsNVONovo Nordisk A/S$60.70-1.1%$56.71$45.05▼$127.61$274.15B0.6613.09 million shs10.73 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie+0.36%+2.37%+6.09%+20.24%+15.31%GSKGSK+0.69%+1.49%+1.91%+5.83%+0.27%NVONovo Nordisk A/S-1.22%+9.13%+6.70%-14.14%-52.40%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$223.09+0.3%$203.75$163.81▼$225.16$393.01B0.534.69 million shs5.99 million shsGSKGSK$40.91+0.6%$38.95$31.72▼$42.63$82.74B0.533.63 million shs3.07 million shsNVONovo Nordisk A/S$60.70-1.1%$56.71$45.05▼$127.61$274.15B0.6613.09 million shs10.73 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie+0.36%+2.37%+6.09%+20.24%+15.31%GSKGSK+0.69%+1.49%+1.91%+5.83%+0.27%NVONovo Nordisk A/S-1.22%+9.13%+6.70%-14.14%-52.40%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABBVAbbVie 2.93Moderate Buy$223.450.17% UpsideGSKGSK 1.86Reduce$37.38-8.64% DownsideNVONovo Nordisk A/S 2.37Hold$81.0033.44% UpsideCurrent Analyst Ratings BreakdownLatest ABBV, NVO, and GSK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/22/2025ABBVAbbVieEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$207.00 ➝ $222.009/17/2025ABBVAbbVieBerenberg BankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$170.00 ➝ $270.009/17/2025NVONovo Nordisk A/SBerenberg BankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy9/16/2025ABBVAbbVieJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$200.00 ➝ $235.009/16/2025NVONovo Nordisk A/SRothschild RedbSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy9/16/2025NVONovo Nordisk A/SRothschild & Co RedburnSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy9/15/2025ABBVAbbVieCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$215.00 ➝ $245.009/12/2025ABBVAbbVieWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$240.00 ➝ $260.009/12/2025ABBVAbbVieBMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$215.00 ➝ $240.009/9/2025NVONovo Nordisk A/SSanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform8/25/2025ABBVAbbVieRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform(Data available from 9/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABBVAbbVie$56.33B7.00$14.97 per share14.90$1.90 per share117.41GSKGSK$40.10B2.08$5.61 per share7.29$8.07 per share5.07NVONovo Nordisk A/S$42.12B6.43$3.86 per share15.74$4.66 per share13.03Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABBVAbbVie$4.28B$2.10106.2315.961.336.45%699.66%13.64%10/29/2025 (Estimated)GSKGSK$3.29B$2.1618.948.802.0310.81%49.22%11.31%10/29/2025 (Estimated)NVONovo Nordisk A/S$14.64B$3.6416.6813.032.3335.60%78.64%24.51%11/5/2025 (Estimated)Latest ABBV, NVO, and GSK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025 NVONovo Nordisk A/S$0.93$0.97+$0.04$0.91$77.51 billion$11.69 billion7/31/2025Q2 2025ABBVAbbVie$3.24$2.97-$0.27$0.52$14.93 billion$15.42 billion7/30/2025Q2 2025GSKGSK$1.12$1.23+$0.11$0.94$7.92 billion$10.64 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABBVAbbVie$6.562.94%N/A312.38%53 YearsGSKGSK$1.684.11%N/A77.78%N/ANVONovo Nordisk A/S$0.821.35%N/A22.53%N/ALatest ABBV, NVO, and GSK DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date9/5/2025ABBVAbbViequarterly$1.643.08%10/15/202510/15/202511/14/20251/1/2100GSKGSKquarterly$0.42064.3%8/15/20258/15/202510/9/20258/6/2025NVONovo Nordisk A/Ssemi-annual$0.41192.4%8/18/20258/18/20258/26/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABBVAbbVie44.140.740.61GSKGSK1.070.870.57NVONovo Nordisk A/S0.520.780.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABBVAbbVie70.23%GSKGSK15.74%NVONovo Nordisk A/S11.54%Insider OwnershipCompanyInsider OwnershipABBVAbbVie0.08%GSKGSK10.00%NVONovo Nordisk A/S0.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABBVAbbVie55,0001.77 billion1.77 billionOptionableGSKGSK68,6292.03 billion1.83 billionOptionableNVONovo Nordisk A/S77,3494.47 billion4.46 billionOptionableABBV, NVO, and GSK HeadlinesRecent News About These CompaniesU.S. Capital Wealth Advisors LLC Acquires 39,215 Shares of Novo Nordisk A/S $NVO2 hours ago | marketbeat.comPark Avenue Securities LLC Buys New Stake in Novo Nordisk A/S $NVO2 hours ago | marketbeat.comNovo Nordisk A/S (NYSE:NVO) Trading Down 1.1% - Here's What HappenedSeptember 22 at 7:16 PM | marketbeat.comNovo Nordisk (NVO) Stock Sinks As Market Gains: Here's WhySeptember 22 at 6:46 PM | zacks.comDEADLINE APPROACHING: Berger Montague Advises Nordisk A/S (NYSE: NVO) Investors to Inquire About a Securities Fraud Class Action by September 30, 2025September 22 at 5:06 PM | prnewswire.comLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 30, 2025 in Novo Lawsuit – NVOSeptember 22 at 3:52 PM | globenewswire.comNovo Nordisk (NYSE:NVO): Assessing Valuation Discrepancy After Recent Market VolatilitySeptember 22 at 3:36 PM | finance.yahoo.comNovo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (Sept 2025)September 22 at 3:36 PM | 247wallst.comNovo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should KnowSeptember 22 at 10:21 AM | zacks.comNovo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before September 30, 2025 to Discuss Your Rights - NVOSeptember 22 at 8:45 AM | prnewswire.comGolden State Equity Partners Acquires 11,983 Shares of Novo Nordisk A/S $NVOSeptember 22 at 7:56 AM | marketbeat.comArlington Partners LLC Increases Stake in Novo Nordisk A/S $NVOSeptember 22 at 7:38 AM | marketbeat.comSHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S (NYSE: NVO)September 22 at 7:30 AM | globenewswire.comNovo Nordisk A/S $NVO Shares Purchased by Ridgewood Investments LLCSeptember 22 at 6:05 AM | marketbeat.comNVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit with the Schall Law FirmSeptember 22 at 5:07 AM | prnewswire.comSeaCrest Wealth Management LLC Sells 4,456 Shares of Novo Nordisk A/S $NVOSeptember 22 at 4:09 AM | marketbeat.comNovo Nordisk A/S $NVO Shares Sold by Wealth Enhancement Advisory Services LLCSeptember 22 at 3:41 AM | marketbeat.comNovo Nordisk’s Woes Are Slimming Denmark’s Economic GrowthSeptember 22 at 2:37 AM | nytimes.comNovo Nordisk: A Guru Buy Amid the Selloff -- Do LEAPS Make Sense?September 22 at 2:37 AM | finance.yahoo.comHere Are 2 Defensive Positions That Are Worth A Look NowSeptember 21 at 10:53 PM | seekingalpha.comNVO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitSeptember 21 at 12:00 PM | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeABBV, NVO, and GSK Company DescriptionsAbbVie NYSE:ABBV$223.08 +0.62 (+0.28%) Closing price 09/22/2025 03:58 PM EasternExtended Trading$222.44 -0.65 (-0.29%) As of 05:37 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.GSK NYSE:GSK$40.91 +0.24 (+0.59%) Closing price 09/22/2025 03:59 PM EasternExtended Trading$40.86 -0.05 (-0.12%) As of 05:42 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.Novo Nordisk A/S NYSE:NVO$60.70 -0.70 (-1.14%) Closing price 09/22/2025 03:59 PM EasternExtended Trading$60.98 +0.28 (+0.46%) As of 05:44 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 High-Yields at 52-Week Lows: Buy, Sell, or Hold Advance Auto Parts is A Great Risk/Reward Play If EPS Delivers 3 Small Caps That Insiders Are Buying Banks Boost Gold Forecasts: One Sees +30% Bull-Case Potential These 3 Stocks Boosting Buybacks Have Rallying Potential GameStop Partying Like It’s 2021: What’s Behind Its 2025 Rebound? Hims & Hers Stock Pushes to Highs on Healthcare Rate Cut Frenzy Why Robinhood Stock Is Soaring—and What Comes Next Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
